Department of General Medicine, University of Poitiers, 6 rue de la Milétrie, TSA 51115, 86073, Poitiers Cedex 9, France.
Clinical Research Unit, Henri Laborit Hospital, 370 av. Jacques cœur, CS 10587, 86021, Poitiers, France.
Eur J Clin Pharmacol. 2019 May;75(5):603-607. doi: 10.1007/s00228-018-02617-6. Epub 2019 Jan 6.
To assess the efficacy of acetylleucine to improve or stop an attack of vertigo and dizziness (vertigo/dizziness).
Systematic review by 2 independent reviewers. Consultation of the Medline, Cochrane and ClinicalTrials.gov databases until September 2018. Keywords used: Acetylleucine, Tanganil®, Acetyl-DL-leucine, Acetyl-leucine. Trial selection: randomised controlled trials (RCTs) comparing acetylleucine against placebo.
Up until 2018, no RCTs have been published on the efficacy of acetylleucine in vertigo/dizziness.
There is no solid evidence of the efficacy of acetylleucine in vertigo/dizziness. Given its frequent prescription and the cost generated for the French social security system, high-quality randomised trials should be carried out to assess its efficacy.
评估乙酰亮氨酸改善或停止眩晕和头晕（眩晕/头晕）发作的疗效。
由 2 名独立评审员进行系统评价。检索 Medline、Cochrane 和 ClinicalTrials.gov 数据库，检索时间截至 2018 年 9 月。使用的关键词：乙酰亮氨酸、坦甘尼、乙酰-DL-亮氨酸、乙酰亮氨酸。试验选择：比较乙酰亮氨酸与安慰剂的随机对照试验（RCT）。
截至 2018 年，尚未发表关于乙酰亮氨酸治疗眩晕/头晕疗效的 RCT。
乙酰亮氨酸治疗眩晕/头晕的疗效尚无确凿证据。鉴于其频繁处方以及给法国社会保障系统带来的费用，应开展高质量的随机试验来评估其疗效。
